10x Genomics, Inc. (TXG)
Nasdaq · Healthcare · Medical Devices
$97.74+4.53%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $12.7B
- Forward P/E
- 1274.8
- 52-week range
- $11.16 – $98.32
- 52-week change
- +639.72%
- EPS (trailing)
- −$0.62
- Analyst rating
- 2.3 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $643M (+5.25%)
- Net income
- −$43.5M
- Operating margin
- −9.5%
- Diluted EPS
- −$0.35
- Free cash flow
- $130M
From the company’s annual report on SEC EDGAR.
About 10x Genomics, Inc.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides.
Headquarters: Pleasanton, United States · 1,178 employees · 10xgenomics.com